Kodak enters molecular imaging
Eastman Kodak Co. has announced the introduction of a new line of digital imaging systems for molecular research.
The company's Image Station In-Vivo FX and F products enable non-invasive measurement of biological processes within living organisms. Conventional diagnostic imaging technologies highlight conditions caused by disease, whereas molecular imaging identifies molecular abnormalities that are the origin of disease at a very early stage -- which can expedite the development of therapeutic pathways that could help cure that disease, the company said.
"Kodak's Image Station In-Vivo FX and F systems represent a significant milestone in our strategy to become a leader in molecular imaging," said Shahram Hejazi, general manager of Kodak's Molecular Imaging Systems unit. "The availability of these innovative molecular imaging systems can significantly enhance research by enabling the visualization of very early disease states. Information obtained about disease origin can lead to development of effective therapeutics."
The company's Image Station In-Vivo FX and F products enable non-invasive measurement of biological processes within living organisms. Conventional diagnostic imaging technologies highlight conditions caused by disease, whereas molecular imaging identifies molecular abnormalities that are the origin of disease at a very early stage -- which can expedite the development of therapeutic pathways that could help cure that disease, the company said.
"Kodak's Image Station In-Vivo FX and F systems represent a significant milestone in our strategy to become a leader in molecular imaging," said Shahram Hejazi, general manager of Kodak's Molecular Imaging Systems unit. "The availability of these innovative molecular imaging systems can significantly enhance research by enabling the visualization of very early disease states. Information obtained about disease origin can lead to development of effective therapeutics."